HIMS is attractive price around 2x gross profit, 10x potentialHims & Hers Health, Inc. Class ABATS:HIMSValuePigHIMS Stock Update: Attractive Valuation Opportunity Hims & Hers Health (HIMS) is now trading at a discounted valuation again—around 1.6x trailing sales (with some sources showing ~1.5–1.7x P/S or EV/Sales as of late February 2026) and roughly 2x gross profit. Growth Potential: The company has strong prospects for high-20% to 30%+ EPS growth over time, alongside high-teens percentage revenue growth. Engagement & Expansion: HIMS boasts a large, loyal fan base and is actively expanding its revenue streams—particularly through its Labs segment, which drives deeper customer engagement via personalized health optimization from blood work analysis. Historical Context: The stock has previously traded as high as 10x sales during peak enthusiasm. Buying near current levels (1.6x or lower) offers compelling long-term upside as HIMS continues scaling both sales and earnings. This appears to be a rare chance to accumulate a high-growth telehealth player at a historically low multiple, especially with its ongoing pivot into broader wellness and personalized medicine. Trade Idea: I am buying shares and selling puts. THe puts will help recoup capital and earn some yield while I wait long term for HIMS to pan out. I am willing to own for 8-10 years but will expect some valatile spikes in both directions up and down that will help harvest some early gains in the shares and also re invest in the dips.